Moreover, phleomycin is only radiomimetic, and unlike EGFR inhibition by monoclonal antibodies, EGFR inhibition by tyrosine kinase inhibitors (TKI) such as erlotinib in colon cancer has not achieved wide clinical utility [36]. This evidence concerns the gene EGFR and malignant colon neoplasm.